BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu ...

CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...

JACKSONVILLE, Fla. – Doctors are warning about a rise in illnesses as 2024 comes to a close, including Norovirus, whooping cough, and seasonal flu. Health experts are urging caution, especially for ...

HilleVax reports Q1 2025 financials: $159.5 million in assets, reduced losses, and ongoing vaccine development for norovirus. HilleVax, Inc. announced its financial results for the first quarter of ...

“Stomach bug,” “cruise-ship virus,” “winter vomiting disease”—all are nicknames for norovirus, the top cause of vomiting, diarrhea, and foodborne illness in the U.S. The contagious ailment typically ...

Tis the season for sniffling, coughing and calling out of work. Here's what to know about the pathogens circulating in the ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase III trial that will test out a vaccine against norovirus, a frequent and ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Steven Lo, CEO, opened by highlighting the lifting of the stop work order on the 10,000 participant portion of Project NextGen Phase 2b COVID-19 vaccine trial, emphasizing, "we are delighted to be ...